438 related articles for article (PubMed ID: 12478660)
1. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling.
Midorikawa Y; Ishikawa S; Iwanari H; Imamura T; Sakamoto H; Miyazono K; Kodama T; Makuuchi M; Aburatani H
Int J Cancer; 2003 Feb; 103(4):455-65. PubMed ID: 12478660
[TBL] [Abstract][Full Text] [Related]
2. Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth.
Capurro MI; Shi W; Sandal S; Filmus J
J Biol Chem; 2005 Dec; 280(50):41201-6. PubMed ID: 16227623
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.
Pan Z; Chen C; Long H; Lei C; Tang G; Li L; Feng J; Chen F
Mol Med Rep; 2013 Mar; 7(3):969-74. PubMed ID: 23338845
[TBL] [Abstract][Full Text] [Related]
4. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
Zittermann SI; Capurro MI; Shi W; Filmus J
Int J Cancer; 2010 Mar; 126(6):1291-301. PubMed ID: 19816934
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Nakatsura T; Yoshitake Y; Senju S; Monji M; Komori H; Motomura Y; Hosaka S; Beppu T; Ishiko T; Kamohara H; Ashihara H; Katagiri T; Furukawa Y; Fujiyama S; Ogawa M; Nakamura Y; Nishimura Y
Biochem Biophys Res Commun; 2003 Jun; 306(1):16-25. PubMed ID: 12788060
[TBL] [Abstract][Full Text] [Related]
6. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
Kwack MH; Choi BY; Sung YK
Mol Cells; 2006 Apr; 21(2):224-8. PubMed ID: 16682817
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG
Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615
[TBL] [Abstract][Full Text] [Related]
9. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling.
Sung YK; Hwang SY; Farooq M; Kim JC; Kim MK
Exp Mol Med; 2003 Aug; 35(4):257-62. PubMed ID: 14508064
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo.
Hartwig S; Hu MC; Cella C; Piscione T; Filmus J; Rosenblum ND
Mech Dev; 2005 Jul; 122(7-8):928-38. PubMed ID: 15925496
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
14. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C
Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714
[TBL] [Abstract][Full Text] [Related]
15. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
16. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
Lai JP; Sandhu DS; Yu C; Han T; Moser CD; Jackson KK; Guerrero RB; Aderca I; Isomoto H; Garrity-Park MM; Zou H; Shire AM; Nagorney DM; Sanderson SO; Adjei AA; Lee JS; Thorgeirsson SS; Roberts LR
Hepatology; 2008 Apr; 47(4):1211-22. PubMed ID: 18318435
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
18. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
Filmus J; Capurro M
FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321
[TBL] [Abstract][Full Text] [Related]
20. The RING domain of PIASy is involved in the suppression of bone morphogenetic protein-signaling pathway.
Imoto S; Sugiyama K; Yamamoto T; Matsuda T
Biochem Biophys Res Commun; 2004 Jun; 319(1):275-82. PubMed ID: 15158472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
